Revolo Biotherapeutics Overview
- Founded
-
2011

- Status
-
Private
- Employees
-
24

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$25.4M
- Investors
-
5
Revolo Biotherapeutics General Information
Description
Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for disease modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis, and inflammatory bowel diseases to avail improved treatment and quick recovery.
Contact Information
Website
www.revolobio.com
Formerly Known As
Peptinnovate, Immune Regulation, Newincco 1132
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- Care/of BCS, Windsor House Station Court
- Station Road Great Shelford
- Cambridge CB22 5NE
- England, United Kingdom
+44 01438 000000
Revolo Biotherapeutics Timeline
Revolo Biotherapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
12. Later Stage VC | 30-Jun-2022 | $25.4M | 000.00 | 00000 | Completed | Generating Revenue |
11. Later Stage VC (Series B) | 18-Nov-2020 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
10. Grant | 01-Jun-2018 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 | |
9. Later Stage VC | 16-May-2018 | 00.000 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
8. Later Stage VC | 14-Jun-2017 | 00.000 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
7. Grant | 01-Jan-2017 | 00000 | 00.000 | Completed | Clinical Trials - Phase 1 | |
6. Later Stage VC | 23-Feb-2016 | 00.000 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
5. Grant | 01-Sep-2015 | 00000 | 00.000 | Completed | Clinical Trials - Phase 1 | |
4. Grant | 01-Aug-2015 | $156K | $1.45M | Completed | Clinical Trials - Phase 1 | |
3. Early Stage VC | 28-Jul-2015 | $506K | $1.45M | 000.00 | Completed | Clinical Trials - Phase 1 |
Revolo Biotherapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C Preferred | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 000 | |
Ordinary | 00,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
Series B Preferred | 0,000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | |
Ordinary | 22,909 | $0.000123 | $160.29 | $160.29 | 1x | $160.29 | 0.47% | |
Ordinary | 30,530 | $0.000123 | $110.97 | $110.97 | 1x | $110.97 | 0.63% |
Revolo Biotherapeutics Patents
Revolo Biotherapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
GB-201809703-D0 | Novel protein with anti-inflammatory properties | Inactive | 13-Jun-2018 | ||
CA-3103370-A1 | Novel protein with anti-inflammatory properties | Pending | 13-Jun-2018 | 000000000 | |
EP-3807303-A1 | Novel protein with anti-inflammatory properties | Pending | 13-Jun-2018 | 000000000 | |
AU-2019285831-A1 | Novel protein with anti-inflammatory properties | Pending | 13-Jun-2018 | 000000000 | |
US-20210238239-A1 | Novel protein with anti-inflammatory properties | Pending | 13-Jun-2018 | A61P19/02 |
Revolo Biotherapeutics Executive Team (14)
Revolo Biotherapeutics Board Members (17)
Name | Representing | Role | Since |
---|---|---|---|
Glen Giovannetti | Self | Board Member | 000 0000 |
Isaac Cheng MD | Morningside Group | Board Member | 000 0000 |
Jonathan Rigby | Self | Group Chief Executive Officer, President & Board Member | 000 0000 |
Marla Persky | Revolo Biotherapeutics | Board Member | 000 0000 |
Michael Albisser | Metellus | Board Member | 000 0000 |
Revolo Biotherapeutics Signals
Revolo Biotherapeutics Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Morningside Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
24Haymarket | Venture Capital | Minority | 000 0000 | 000000 0 | |
NCL Technology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Innovate UK | Government | 000 0000 | 000000 0 | ||
Metellus | Family Office | Minority | 000 0000 | 000000 0 |